RE: Skinbiotix10 Jan 2022 18:01
Belgrano, do you spend all your time stuck in front of a screen monitoring SBTX comms? You’re like a mother hen clucking around protecting her brood from perceived dangers. We’re not all gifted with your rose-tinted specs or long list of ‘contacts’ in the know. You're clearly troubled by any opinions that don’t fall in line with your own subjective, dare I say it, rampastic view. However, many of us, like me, rely on their own research and investment strategy. We tend not to be swayed by any form of bias on these boards, positive or negative. Instead of accusing individuals, who might have a different view, even slight, to your own, of being trolls, derampers or whatever, you should be encouraging as many different points of view as possible. You never know you might learn something!
Now for my earlier post. Suggest you read again and have a think! The hype pre-launch of AxisBiotix was based on study results not a trial. In the short to medium term, the only clear and valid direction we will get on the success of this supplement will be from sales data backed-up by validated user experiences. The launch, as I point out, was not a success from an investor’s standpoint. Just look at the sp! Furthermore, from what I can see there has been zero publicity which one would have expected if AxisBiotix was as ground-breaking as has been suggested. Why is this, as it is potentially a huge story given the difficulties experienced by psoriasis sufferers?
So what is going to provide a positive sp uplift? Certainly not AxisBiotix and the evidence is staring us all in the face. Short term it can only be a Sederma announcement. I rest my case!
Sign In
Follow the stocks
